These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10613369)

  • 21. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin.
    Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM
    J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinupristin-dalfopristin.
    Bryson HM; Spencer CM
    Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.
    Summers M; Misenhimer GR; Antony SJ
    South Med J; 2001 Mar; 94(3):353-5. PubMed ID: 11284529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA approves quinupristin-dalfopristin for some vancomycin-resistant infections.
    Miller JL
    Am J Health Syst Pharm; 1999 Nov; 56(21):2174. PubMed ID: 10565689
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.
    Raad I; Hachem R; Hanna H; Girgawy E; Rolston K; Whimbey E; Husni R; Bodey G
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3202-4. PubMed ID: 11600379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Quinupristin/dalfopristin].
    Escolar M; Azanza JR; Cárdenas E; Muñoz MJ
    Rev Med Univ Navarra; 2001; 45(4):43-54. PubMed ID: 11985218
    [No Abstract]   [Full Text] [Related]  

  • 28. Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination.
    Griswold MW; Lomaestro BM; Briceland LL
    Am J Health Syst Pharm; 1996 Sep; 53(17):2045-53. PubMed ID: 8870891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.
    Bergeron M; Montay G
    J Antimicrob Chemother; 1997 May; 39 Suppl A():129-38. PubMed ID: 9511077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the quinupristin/dalfopristin breakpoints for Enterococcus faecium.
    Hammerum AM; Agersø Y; Garcia-Migura L; Mette Seyfarth A; Porsbo LJ; Emborg HD; Bogø Jensen L
    Int J Antimicrob Agents; 2009 Sep; 34(3):288-90. PubMed ID: 19409762
    [No Abstract]   [Full Text] [Related]  

  • 31. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience.
    Low DE
    Microb Drug Resist; 1995; 1(3):223-34. PubMed ID: 9158779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
    Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
    J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinupristin-dalfopristin use in children is associated with arthralgias and myalgias.
    Gupte G; Jyothi S; Beath SV; Kelly DA
    Pediatr Infect Dis J; 2006 Mar; 25(3):281. PubMed ID: 16511403
    [No Abstract]   [Full Text] [Related]  

  • 34. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
    Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
    Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New macrolides, azalides and streptogramins; current role and their future perspective].
    Hoepelman IM; Verhoef J
    Ned Tijdschr Geneeskd; 1992 Sep; 136(38):1847-51. PubMed ID: 1407149
    [No Abstract]   [Full Text] [Related]  

  • 36. [Acute hemorrhagic diarrhea caused by Klebsiella oxytoca: associated with virginiamycin?].
    Terrier F; Algayres JP; Le Romancer JM; Gerome P; Bili H; Daly JP
    Presse Med; 1995 Oct; 24(31):1446. PubMed ID: 8545338
    [No Abstract]   [Full Text] [Related]  

  • 37. Quinupristin-dalfopristin and linezolid: evidence and opinion.
    Eliopoulos GM
    Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro combinations of five intravenous antibiotics with dalfopristin-quinupristin against Staphylococcus aureus in a 3-dimensional model.
    Duez JM; Adochitei A; Péchinot A; Siebor E; Sixt N; Neuwirth C
    J Chemother; 2008 Dec; 20(6):684-9. PubMed ID: 19129064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency.
    Chevalier P; Rey J; Pasquier O; Leclerc V; Baguet JC; Meyrier A; Harding N; Montay G
    Clin Pharmacokinet; 2000 Jul; 39(1):77-84. PubMed ID: 10926351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Other antimicrobials (linezolid, quinupristin/dalfopristin)].
    Yamaguchi K; Ohno A
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():756-61. PubMed ID: 12722312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.